Ana Gene Biotech
Mouse move on Image to zoom

AML TransFind Kit

- Detection of the most important AML translocations
- Real-time PCR TaqMan Probe Technology,
- Highly Sensitive Detection Kit.

Catalog Number Description (12 samples)
- K2002: 2X version , 12 samples
- K2002L: Lyophilized version , 12 samples (containing Lyophilized qPCR Mixes)

Lyophilized Version Price :
Old Price :
    •  Jan 2017
    •  2017

AML TransFind Kit

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. The symptoms of AML include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. A number of risk factors for developing AML have been identified, including: other blood disorders, chemical exposures, ionizing radiation, and genetics. A hereditary risk for AML appears to exist. There are numerous reports of multiple cases of AML developing in a family at a rate higher than predicted by chance alone. A sample of marrow or blood is typically also tested for chromosomal translocations by routine cytogenetics, fluorescent in situ hybridization and RT-PCR. Genetic studies may also be performed to look for specific mutations in genes such as MLL, FLT3, NPM1, and KIT, which may influence the outcome of the disease. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive. This kit is based on Real-time PCR - Taqman Probe technology for detection of important translocations of AML. Translocations that available in this kit including AML1/ETO - t(8;21), CBFb/MYH11 - inv(16), MLL/AF9 - t(9;11), MLL/AF6 - t(6;11) and PML/RARa - t(15;17). The fusion transcripts are detected in the FAM channel and Internal control (ABL1 gene) is detected in the Yellow channel.

AML TransFind Kit

- CBFB/MYH11qPCR Mix (Lyophilized or 2X)
- AML1/ETO qPCR Mix (Lyophilized or 2X)
- PML/RARa qPCR Mix (Lyophilized or 2X)
- MLL/AF9 qPCR Mix (Lyophilized or 2X)
- MLL/AF6 qPCR Mix (Lyophilized or 2X)
- Dilution Buffer (only for lyophilized version)
- Positive Conrol Mix
- Water Nuclease free
- Quick Protocol
- mini CD

AML TransFind Kit

I. Sample Requirement
RNA from Peripheral blood: 0.5 - 1mL
RNA from Bone from marrow: 0.5 - 1mL

II. Sensitivity
These reagents detect 10 copies of AML associated fusion transcripts. Sensitivity of the assay was
determined by serially diluting the positive control of AML associated fusion transcripts from 100 to 1
copy/PCR. Sensitivity of the assay was determined as 10 copies/PCR. This means that there is 95%
probability that 10 Copies/PCR will be detected.
III. Module Specificity
Test result will be positive, only to AML associated fusion transcripts. The primers and probes were checked
for possible homologies to all published sequences (Genbank) by BLAST analysis to avoid any homology
with other organisms.
IV. Reproducibility
Systematic kit production and strict quality control system eliminate batch variation of products. Thus, users
can get reproducible data even though they use different batch of product.
V. Quality Control
Functionality tested in PCR for specificity, sensitivity and reproducibility for specific probe/primer using
hematopoietic cell lines, blood positive and negative samples.
VI. Speed
Total reaction time is less than 2 hour.

AML TransFind Kit

1. This Kit is intended for molecular biology applications and is not intended for the prevention or treatment of a disease.

2. All reagents may exclusively be used for in vitro diagnostics.

3. The product is to be used by personnel specially instructed and trained in for the in-vitro diagnostics procedures only.

4. It is important to pipet the indicated quantities, and mix well after each reagent addition. Check pipettes regularly.

5. Instructions must be followed correctly in order to obtain correct results.

6. This test has been validated for use with the reagents provided in the kit. The use of other Reagents or methods, or the
use of equipment not fulfilling the specifications, may render equivocal results.

7. Detection of translocation depends on the number of fusion transcripts present in the sample, and can be affected by
sample collection methods, patient-related factors (e.g. age, symptoms) or for infection stage and sample size.

8. Cross contamination between samples and exogenous cDNA can only be avoided by following good laboratory

9. Attention should be paid to expiration dates printed on the kit box. Do not use expired product.

AML TransFind Kit

1. Jemal A, et al. Cancer statistics, 2002. CA Cancer J Clin; 52(1): 23-47.

2. Baldus CD, et al. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by
molecular genetic alterations: a concise review. 2007. Br. J. Haematol; 137 (5): 387-400.

3. Seiter, Karen, et al. Acute myeloid leukemia staging. 2011. http://emedicine

  • Free shipping
  • Best Price
  • Two years waranty on every product
  • Available on diffrent colors
  • Product Code: 54
  • Reward Points:
  • Availability: False
  • Old Price: $0
  • Ex Tax: $0.0
  • Ex Tax: $0.0
  • Product Code: 54
  • Reward Points:

Write a Review

Leave a comment


Comments (0)

Popular Brands See Our Popular Brands